NRX Pharmaceuticals reported a net loss of $20.1 million for the nine months ended September 30, 2026, an improvement from the $29.0 million loss in the prior year period. The company significantly increased its cash position to $19.8 million through various equity offerings, while net patient service revenue grew to $3.3 million.
NRx Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine ahead of its November 10 goal date. The product is an American-manufactured formulation that eliminates the use of benzethonium chloride, a preservative the FDA has declined to designate as safe. The company aims to address the ongoing national shortage of ketamine using modern high-volume manufacturing technology in partnership with Nephron Pharmaceuticals.
“We are excited to bring Preservative-Free Ketamine to market and to give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in multiple product categories by the US Food and Drug Administration.”
Jonathan Javitt, MD, MPH, the company’s Chairman and Chief Executive Officer
NRx Pharmaceuticals has scheduled its 2026 Annual Meeting of Stockholders for December 17, 2026, to be held in a virtual-only format. The company established October 28, 2026, as the record date and set October 25, 2026, as the new deadline for stockholder proposals and director nominations. These deadlines were revised because the meeting date is more than 30 days from the anniversary of the previous year's annual meeting.
NRX Pharmaceuticals Wins $11.2M Contract from Defense Advanced Research Projects Agency
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, was awarded an $11.2 million prime contract from DARPA to conduct the SPARC-TMS clinical trial. The trial evaluates a single-day treatment protocol combining robotic neuro-navigated transcranial magnetic stimulation with the company's investigational drug, NRX-101, for treatment-resistant depression. The contract includes an initial obligation of $6.7 million with additional funding subject to appropriations and performance milestones.